Skip to main content
main-content

Lung and thoracic cancers

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

medwireNews top story

CASPIAN: Durvalumab addition boosts SCLC survival

IV drip 2

Adding durvalumab to first-line chemotherapy significantly improves the overall survival of patients with extensive-stage small-cell lung cancer, a phase III trial shows.

medwireNews top story

Combining local and systemic therapy improves survival for advanced NSCLC

Lung radiographs_operation theatre

In patients with stage IV non-small-cell lung cancer, the addition of surgical resection or external beam radiotherapy/thermal ablation to systemic therapy increases overall survival versus systemic therapy alone, suggests a comparative effectiveness study.

medwireNews top story

Early data show promise for the FGFR inhibitor rogaratinib

Pills in hand

The FGFR inhibitor rogaratinib is well tolerated and clinically active in patients with various tumor types selected for treatment on the basis of FGFR mRNA overexpression, phase I study data show.

medwireNews top story

Local ablative therapy–pembrolizumab benefit suggested for metastatic NSCLC

Lung cancer illustration

Data from two phase II studies published in JAMA Oncology lend support to the sequential use of local ablative therapy and PD-1 blockade in patients with metastatic non-small-cell lung cancer.

Expert opinion

Immunotherapy for patients with metastatic NSCLC harboring an EGFR mutation

DNA samples

Management of EGFR-mutant non-small-cell lung cancer has been dominated by targeted therapies, but it is less clear where immunotherapy will fit into the treatment paradigm. Charu Aggarwal (University of Pennsylvania, USA) explores the current place of immunotherapy in treating this disease.

Expert opinion

Management of EGFR mutation-positive NSCLC: Two steps forward, looking back

Adenocarcinoma histology

Caroline McCoach (Helen Diller Family Comprehensive Cancer Center, CA, USA) and Howard (Jack) West (Swedish Cancer Institute, WA, USA) discuss the way forward after great progress with tyrosine kinase inhibitors targeting the epidermal growth factor receptor in non-small-cell lung cancer.

Expert opinion

Choosing an immunotherapy approach in patients with advanced NSCLC

Advanced NSCLC

Liza Villaruz (Hillman Cancer Center, PA, USA) examines recent KEYNOTE trials investigating pembrolizumab for advanced non-small-cell lung cancer and the questions they raise regarding patient selection and combination therapy.

View from the clinic

Explaining immunotherapy to our patients with NSCLC

Explaining immunotherapy

Immunotherapy is changing practice in lung cancer, and with this, patient education. In this 'View from the clinic' article, Advisory Board member Beth Eaby-Sandy (Abramson Cancer Center, PA, USA) describes how she explains the new immunotherapy treatments to her patients. 

13-09-2019 | Surgery | Video | Article

Researcher comment: VIOLET results support VATS for lung cancer resection

WATCH | Eric Lim describes the findings of the VIOLET trial comparing video-assisted thoracoscopic lobectomy and open lobectomy for early-stage lung cancer (1:57).

13-09-2019 | Small-cell lung cancer | Video | Article

Expert comment: CASPIAN trial of durvalumab in SCLC

WATCH | Raffaele Califano comments on the CASPIAN trial of front-line durvalumab plus chemotherapy in extensive-stage small-cell lung cancer, and puts the findings in context of the IMpower133 study of atezolizumab in the same setting (3:30).

12-09-2019 | Screening | Video | Article

Researcher comment: ILST findings support novel eligibility criteria

WATCH | Stephen Lam discusses the interim findings from the International Lung Screen Trial indicating that changing eligibility criteria can improve identification of high-risk individuals (5:36).

10-09-2019 | Lung cancer | Video | Article

Researcher comment: Combining microRNAs and LDCT to assess lung cancer risk profiles

WATCH | Ugo Pastorino discusses the bioMILD study, which investigates a lung cancer screening program that supplements low-dose computed tomography with a blood microRNA assay (3:09).

10-09-2019 | Non-small cell lung cancer | Video | Article

Researcher comment: AMG 510 for KRAS mutation-positive NSCLC

WATCH | Ramaswamy Govindan outlines the key findings of the non-small-cell lung cancer cohort of the phase I trial of the novel KRAS inhibitor AMG 510, and comments on the next steps for the research (5:34).

09-09-2019 | Non-small cell lung cancer | Video | Article

Researcher comment: TMB not prognostic for KEYNOTE-189 participant outcomes

WATCH | Marina Garassino reports the KEYNOTE-189 tumor mutational burden analysis and what the findings mean for this biomarker (4:03).

Content collection

Brain metastases in NSCLC

Brain MRI

A content collection providing HCPs with education around the burden, diagnosis and treatment of brain metastases arising from NSCLC.

Made possible by independent educational funding provided by AstraZeneca.

28-02-2019 | Lung cancer | At a glance | Article

At a glance: CheckMate lung cancer trials

Here we round up the CheckMate trials evaluating the PD-1 inhibitor nivolumab in non-small-cell lung cancer and small-cell lung cancer.

28-01-2019 | Immunotherapy | Podcast | Audio

Understanding the relationship between the gut microbiome and immunotherapy

Jennifer Wargo, from The University of Texas MD Anderson Cancer Center in Houston, USA, shares her insights into recent research showing an association between intestinal microbiota and response to immunotherapy (13:27).

12-12-2018 | Immunotherapy | Feature | Article

Hyperprogression as a response to immunotherapy: ‘A serious downside’

In light of recent reports of hyperprogression in response to treatment with cancer immunotherapy, medwireNews spoke to medical oncologist Razelle Kurzrock (University of California, San Diego, La Jolla, USA) about the phenomenon, the implications for therapy, and future directions for research.

Journal articles and book chapters

17-06-2019 | Small-cell lung cancer | Article

Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Partially Realized Potential

Armstrong SA & Liu SV. Adv Ther 2019. doi:10.1007/s12325-019-01008-2

04-02-2019 | Non-small cell lung cancer | Article

Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC

Camidge DR et al. Nat Rev Clin Oncol 2019; 16(6): 341-355. doi:10.1038/s41571-019-0173-9.

26-11-2018 | EGFR inhibitors | Article

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer

Shah KN et al. Nat Med 2019; 25(1): 111-118. doi:10.1038/s41591-018-0264-7

08-11-2018 | Non-small cell lung cancer | Article

Risk factors for brain metastases in patients with non–small‐cell lung cancer

Ning An, Wang Jing, Haoyi Wang, Ji Li, Yang Liu, Jinming Yu, Hui Zhu. Cancer Med 2018;7(12): 6357-6364. doi:10.1002/cam4.1865.

21-10-2018 | Non-small cell lung cancer | Article

Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors

Wrona A et al. Cancer Treat Rev 2018; 71: 59–67. doi:10.1016/j.ctrv.2018.10.011.

Reference

01-02-2017 | Immunotherapy | Primer | Collection

The fundamentals of cancer immunotherapy

A introductory guide to cancer immunotherapy for non-specialists, focusing primarily on the mechanisms of immune checkpoint inhibition and the role of these agents in anticancer therapy.

12-04-2018 | EGFR signalling | Primer | Collection

EGFR signaling in cancer

This downloadable powerpoint slide set includes a variety of high quality illustrations relating to the role of the epidermal growth factor receptor pathway in the pathogenesis and progression of cancer and as a target for anti-cancer therapy.

28-02-2019 | Lung cancer | At a glance | Article

At a glance: CheckMate lung cancer trials

Here we round up the CheckMate trials evaluating the PD-1 inhibitor nivolumab in non-small-cell lung cancer and small-cell lung cancer.

Our Editorial Board advisor

Fiona Blackhall

Dr Blackhall is a Professor of Thoracic Oncology with expertise in personalized medicine and circulating biomarkers within the Institute of Cancer Studies, University of Manchester and has been a Consultant Medical Oncologist at The Christie Hospital, Manchester since 2005. She has conducted over 50 therapeutic clinical trials, including practice-changing precision medicine studies, and led on new directions in radiotherapy-related research and supportive palliative care research.

Image Credits